CH de Périgueux

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS	Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome	Active, not recruiting	Phase 3	2026-09-11		NCT03223961
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms	Embolism and Thrombosis, Hemic and Lymphatic Diseases, Hemorrhage, Myeloproliferative Disorders, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, cellular phase chronic idiopathic myelofibrosis, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease, vascular disorder, venous thromboembolism	Recruiting	Phase 3	2026-03-20		NCT05198960

Clinical trials